Share on StockTwits

Investment analysts at Topeka Capital Markets hoisted their target price on shares of Omnicell (NASDAQ:OMCL) from $30.00 to $31.00 in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Topeka Capital Markets’ price objective indicates a potential upside of 10.56% from the stock’s previous close.

Omnicell (NASDAQ:OMCL) opened at 28.04 on Thursday. Omnicell has a 52 week low of $20.88 and a 52 week high of $30.33. The stock has a 50-day moving average of $27. and a 200-day moving average of $27.51. The company has a market cap of $1.006 billion and a P/E ratio of 36.04.

Omnicell (NASDAQ:OMCL) last released its earnings data on Thursday, July 31st. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.29 by $0.01. The company had revenue of $105.10 million for the quarter, compared to the consensus estimate of $103.23 million. During the same quarter last year, the company posted $0.27 earnings per share. Omnicell’s revenue was up 12.2% compared to the same quarter last year. Analysts expect that Omnicell will post $1.23 EPS for the current fiscal year.

Separately, analysts at Zacks upgraded shares of Omnicell from a “neutral” rating to an “outperform” rating in a research note on Friday, August 8th. They now have a $32.00 price target on the stock. Seven analysts have rated the stock with a buy rating, Omnicell currently has an average rating of “Buy” and a consensus price target of $31.43.

In other Omnicell news, VP Dan S. Johnston sold 6,250 shares of Omnicell stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $28.00, for a total value of $175,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Receive News & Ratings for Omnicell Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.